InterMune Price Target Increased to $33.00 by Analysts at Credit Suisse (ITMN)
Stock analysts at Credit Suisse lifted their price target on shares of InterMune (NASDAQ:ITMN) from $15.00 to $33.00 in a report issued on Wednesday, Stock Ratings Network reports. The firm currently has a “neutral” rating on the stock. Credit Suisse’s price target points to a potential upside of 7.67% from the company’s current price.
The analysts wrote, “Our $33 TP, Esbriet estimates, and P&L modeling remain unchanged (after our inclusion of US Esbriet revenues following positive ASCEND data earlier this week). With the stock price around our target price and the balance of risk/reward reflected in the stock price, we move ITMN to Neutral based on the key points/observations below.”
InterMune (NASDAQ:ITMN) opened at 30.65 on Wednesday. InterMune has a 52 week low of $8.61 and a 52 week high of $38.73. The stock has a 50-day moving average of $16.29 and a 200-day moving average of $14.70. The company’s market cap is $2.750 billion. InterMune also was the target of unusually large options trading activity on Tuesday. Stock traders bought 25,056 call options on the company. This is an increase of approximately 667% compared to the typical volume of 3,267 call options.
Other equities research analysts have also recently issued reports about the stock. Analysts at Robert W. Baird raised their price target on shares of InterMune to $44.00 in a research note on Tuesday. Separately, analysts at Oppenheimer raised their price target on shares of InterMune from $19.00 to $42.00 in a research note on Tuesday. Finally, analysts at Wells Fargo & Co. raised their price target on shares of InterMune to $43.00 in a research note on Tuesday. Five analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $34.09.
InterMune, Inc (NASDAQ:ITMN), is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.